View Item 

Show simple item record

Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein–Barr virus IgG antibody titers

dc.contributor.authorWatt, Tessaen_US
dc.contributor.authorOberfoell, Stephanieen_US
dc.contributor.authorBalise, Raymonden_US
dc.contributor.authorLunn, Mitchell R.en_US
dc.contributor.authorKar, Aroop K.en_US
dc.contributor.authorMerrihew, Lindseyen_US
dc.contributor.authorBhangoo, Munveer S.en_US
dc.contributor.authorMontoya, José G.en_US
dc.date.accessioned2012-11-07T17:04:27Z
dc.date.available2014-02-03T16:21:43Zen_US
dc.date.issued2012-12en_US
dc.identifier.citationWatt, Tessa; Oberfoell, Stephanie; Balise, Raymond; Lunn, Mitchell R.; Kar, Aroop K.; Merrihew, Lindsey; Bhangoo, Munveer S.; Montoya, José G. (2012). "Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epsteinâ Barr virus IgG antibody titers ." Journal of Medical Virology 84(12): 1967-1974. <http://hdl.handle.net/2027.42/94236>en_US
dc.identifier.issn0146-6615en_US
dc.identifier.issn1096-9071en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/94236
dc.description.abstractValganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV‐6) and Epstein–Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV‐6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900 mg valganciclovir daily (55 of whom took an induction dose of 1,800 mg daily for the first 3 weeks). Antibody titers were considered high if HHV‐6 IgG ≥1:320, EBV viral capsid antigen (VCA) IgG ≥1:640, and EBV early antigen (EA) IgG ≥1:160. Patients self‐rated physical and cognitive functioning as a percentage of their functioning prior to illness. Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning. Thirty‐two patients (52%) were categorized as responders. Among these, 19 patients (59%) responded physically and 26 patients (81%) responded cognitively. Baseline antibody titers showed no significant association with response. After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively ( P  < 0.0001). Longer treatment was associated with improved response ( P  = 0.0002). No significant difference was found between responders and non‐responders among other variables analyzed. Valganciclovir treatment, independent of the baseline antibody titers, was associated with self‐rated improvement in physical and cognitive functioning for CFS patients who had positive HHV‐6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response. J. Med. Virol. 84:1967–1974, 2012. © 2012 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherEBVen_US
dc.subject.otherCFSen_US
dc.subject.otherHHV‐6en_US
dc.titleResponse to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein–Barr virus IgG antibody titersen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum5 University of Michigan Medical School, 1301 Catherine Road, Ann Arbor, MI 48109.en_US
dc.contributor.affiliationotherDepartment of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115.en_US
dc.contributor.affiliationotherSan Diego School of Medicine, University of California, 8950 Villa La Jolla Drive, San Diego, CA 92037.en_US
dc.contributor.affiliationotherStanford University School of Medicine, 300 Pasteur Drive, Room S‐101, Stanford, CA 94305.en_US
dc.contributor.affiliationotherDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Palo Alto, Californiaen_US
dc.contributor.affiliationotherStanford University School of Medicine, Health Research and Policy, Stanford, Californiaen_US
dc.contributor.affiliationotherStanford University School of Medicine, Stanford, Californiaen_US
dc.contributor.affiliationotherPalo Alto Medical Foundation, Research Institute, Palo Alto, Californiaen_US
dc.contributor.affiliationotherLos Angeles David Geffen School of Medicine, University of California, 1633 Bruin Street, Los Angeles, CA 90047.en_US
dc.identifier.pmid23080504en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/94236/1/23411_ftp.pdf
dc.identifier.doi10.1002/jmv.23411en_US
dc.identifier.sourceJournal of Medical Virologyen_US
dc.identifier.citedreferenceKomaroff AL. 2006. Is human herpesvirus‐6 a trigger for chronic fatigue syndrome ? J Clin Virol 37: S39 – S46.en_US
dc.identifier.citedreferenceAblashi DV, Devin CL, Yoshikawa T, Lautenschlager I, Luppi M, Kuhl U, Komaroff AL. 2010. Review Part 3: Human herpesvirus‐6 in multiple non‐neurological diseases. J Med Virol 82: 1903 – 1910.en_US
dc.identifier.citedreferenceAfari N, Buchwald D. 2003. Chronic fatigue syndrome: A review. Am J Psychiat 160: 221 – 236.en_US
dc.identifier.citedreferenceAmanna IJ, Carlson NE, Slifka MK. 2007. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903 – 1915.en_US
dc.identifier.citedreferenceAmbinder RF. 2003. Epstein‐Barr virus‐associated lymphoproliferative disorders. Rev Clin Exp Hematol 7: 362 – 374.en_US
dc.identifier.citedreferenceAmbinder RF, Lin L. 2005. Mononucleosis in the laboratory. J Infect Dis 192: 1503 – 1504.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention (CDC). Chronic Fatigue Syndrome—Updated May 16, 2012. Available from: http://www.cdc.gov/cfs/en_US
dc.identifier.citedreferenceCuomo L, Trivedi P, de Grazia U, Calogero A, D'Onofrio M, Yang W, Frati L, Faggioni A, Rymo L, Ragona G. 1998. Upregulation of Epstein‐Barr virus‐encoded latent membrane protein by human herpesvirus 6 superinfection of EBV‐carrying Burkitt lymphoma cells. J Med Virol 55: 219 – 226.en_US
dc.identifier.citedreferenceFlamand L, Stefanescu I, Ablashi DV, Menezes J. 1993. Activation of the Epstein‐Barr virus replicative cycle by human herpesvirus 6. J Virol 67: 6768 – 6777.en_US
dc.identifier.citedreferenceFlamand L, Komaroff AL, Arbuckle JH, Medveczky PG, Ablashi DV. 2010. Review, part 1: Human herpesvirus‐6‐basic biology, diagnostic testing, and antiviral efficacy. J Med Virol 82: 1560 – 1568.en_US
dc.identifier.citedreferenceFotheringham J, Williams EL, Akhyani N, Jacobson S. 2008. Human herpesvirus 6 (HHV‐6) induces dysregulation of glutamate uptake and transporter expression in astrocytes. J Neuroimmune Pharm 3: 105 – 116.en_US
dc.identifier.citedreferenceFukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. 1994. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953 – 959.en_US
dc.identifier.citedreferenceHickie I, Davenport T, Wakefield D, Vollmer‐Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A. 2006. Post‐infective and chronic fatigue syndromes precipitated by viral and non‐viral pathogens: Prospective cohort study. Brit Med J 333: 575 – 578.en_US
dc.identifier.citedreferenceHill JA, Koo S, Guzman Suarez BB, Ho VT, Cutler C, Koreth J, Armand P, Alyea EP III, Baden LR, Antin JH, Soiffer RJ, Marty FM. 2012. Cord‐blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus‐6‐associated acute limbic encephalitis: A cohort analysis. Biol Blood Marrow Transplant 1 – 11; [Epub ahead of print].en_US
dc.identifier.citedreferenceHollsberg P, Kusk M, Bech E, Hansen HJ, Jakobsen J, Haahr S. 2005. Presence of Epstein‐Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: Associations with disease activity. Acta Neurol Scand 112: 395 – 402.en_US
dc.identifier.citedreferenceJason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang CF, Plioplys S. 1999. A community‐based study of chronic fatigue syndrome. Arch Intern Med 159: 2129 – 2137.en_US
dc.identifier.citedreferenceJason LA, Corradi K, Torres‐Harding S, Taylor RR, King C. 2005. Chronic fatigue syndrome: The need for subtypes. Neuropsychol Rev 15: 29 – 58.en_US
dc.identifier.citedreferenceKogelnik AM, Loomis K, Hoegh‐Petersen M, Rosso F, Hirschier C, Montoya JG. 2006. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus‐6 (HHV‐6) and Epstein‐Barr Virus (EBV) who were experiencing central nervous system dysfunction including long‐standing fatigue. J Clin Virol 37: S33 – S38.en_US
dc.identifier.citedreferenceKomaroff AL. 1988. Chronic fatigue syndromes: Relationship to chronic viral infections. J Virol Methods 21: 3 – 10.en_US
dc.identifier.citedreferenceKomaroff AL, Buchwald DS. 1998. Chronic fatigue syndrome: An update. Annu Rev Med 49: 1 – 13.en_US
dc.identifier.citedreferenceKrueger GR, Ablashi DV. 2003. Human herpesvirus‐6: A short review of its biological behavior. Intervirology 46: 257 – 269.en_US
dc.identifier.citedreferenceKuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. 2005. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112: 1965 – 1970.en_US
dc.identifier.citedreferenceLerner MA, Beqaj SH, Fitzgerald JT. 2008. Validation of the energy index point score to serially measure the degree of disability in patients with chronic fatigue syndrome. In Vivo 22: 799 – 801.en_US
dc.identifier.citedreferenceLerner MA, Beqaj SH, Fitzgerald JT, Gill K, Gill C, Edington J. 2010. Subset‐directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome. Virus Adapt Treat 2: 11.en_US
dc.identifier.citedreferenceLeveque N, Boulagnon C, Brasselet C, Lesaffre F, Boutolleau D, Metz D, Fornes P, Andreoletti L. 2011. A fatal case of Human Herpesvirus 6 chronic myocarditis in an immunocompetent adult. J Clin Virol 52: 142 – 145.en_US
dc.identifier.citedreferenceMori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, Saito N, Kato K, Takenaka K, Iwasaki H, Harada N, Abe Y, Teshima T, Akashi K. 2010. High incidence of human herpes virus 6‐associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant 16: 1596 – 1602.en_US
dc.identifier.citedreferenceReynolds WJ, Vernon SD, Bouchery E, Reeves WC. 2004. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc 2: 4 – 12.en_US
dc.identifier.citedreferenceSairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T. 1995. Antibody responses to Epstein‐Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 38: 269 – 273.en_US
dc.identifier.citedreferenceYao K, Crawford JR, Komaroff AL, Ablashi DV, Jacobson S. 2010. Review part 2: Human herpesvirus‐6 in central nervous system diseases. J Med Virol 82: 1669 – 1678.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
23411_ftp.pdf
Size:
478.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.